Conduction system pacing in heart failure: Time for a paradigm shift?

Panayotis K Vlachakis1, Panagiotis Theofilis2, Anastasios Apostolos2

  • 1First Department of Cardiology, National and Kapodistrian University of Athens, School of Medicine "Hippokration" General Hospital, 114 Vasilissis Sofias avenue, Athens, 11527, Greece. vlachakispanag@gmail.com.

Heart Failure Reviews
|November 23, 2024
PubMed

Insights

Conduction system pacing (CSP) shows promise for heart failure (HF) patients with electrical issues. Further research, including randomized controlled trials (RCTs), is needed to confirm long-term benefits and refine techniques for widespread clinical use.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • Heart failure (HF) presents significant morbidity and mortality, often linked to electrical conduction abnormalities.
  • Conventional pacing techniques may yield suboptimal outcomes in HF patients with these abnormalities.
  • Conduction system pacing (CSP) offers a novel approach targeting the heart's natural conduction system.

Purpose of the Study:

  • To review the current status and future directions of conduction system pacing (CSP) in heart failure (HF) management.
  • To highlight the potential benefits and existing challenges of CSP for HF patients.
  • To emphasize the need for further research, particularly randomized controlled trials (RCTs).

Main Methods:

  • Review of current literature and observational studies on CSP in HF.
  • Analysis of recent guideline recommendations regarding CSP.
  • Discussion of technical challenges and future technological integration in CSP.

Main Results:

  • CSP, including His bundle pacing and left bundle branch area pacing, is recommended for specific HF populations based on observational data.
  • Existing data are primarily from observational studies, limiting definitive conclusions on long-term outcomes.
  • Technical challenges in lead implantation and mechanical stress require further investigation.

Conclusions:

  • CSP holds potential for improving HF management by addressing electrical conduction abnormalities.
  • Routine clinical implementation requires clarification of practical considerations and resolution of technical challenges.
  • Large-scale RCTs are crucial to establish efficacy, identify optimal candidates, and guide future CSP practices in HF.

Related Concept Videos

Conduction System of the Heart01:19

Conduction System of the Heart

Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
4.5K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
Electrophysiology of Normal Cardiac Rhythm01:19

Electrophysiology of Normal Cardiac Rhythm

The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
2.1K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316